Ruggiero Salvatore L, Mehrotra Bhoomi
New York Center for Orthognathic and Maxillofacial Surgery, Lake Success, New York 11042, USA.
Annu Rev Med. 2009;60:85-96. doi: 10.1146/annurev.med.60.063007.134350.
Bisphosphonate therapy has been considered standard therapy in the management and care of cancer patients with metastatic bone disease and patients with osteoporosis. The efficacy of these drugs is due to their ability to inhibit osteoclast-mediated bone resorption. However, the postmarketing experience with intravenous and, to a much lesser extent, oral bisphosphonates has raised concerns about potential side effects related to profound bone remodeling inhibition and osteonecrosis isolated to the jaws. We review the risk factors, incidence, pathogenesis, prevention strategies, and management of this new complication.
双膦酸盐疗法一直被视为转移性骨病癌症患者和骨质疏松症患者管理与护理中的标准疗法。这些药物的疗效归因于它们抑制破骨细胞介导的骨吸收的能力。然而，静脉注射双膦酸盐以及程度轻得多的口服双膦酸盐的上市后经验引发了人们对与严重骨重塑抑制和颌骨局限性骨坏死相关的潜在副作用的担忧。我们回顾了这种新并发症的危险因素、发病率、发病机制、预防策略及管理方法。
